Ryo Ariyasu

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Real-World Survival Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors.

Real-World Survival Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors.

Journal: Thoracic cancer

Published: February 16, 2026

Timing and Risk Factors for Hyperglycemia Associated With Anamorelin Administration.

Timing and Risk Factors for Hyperglycemia Associated With Anamorelin Administration.

Journal: Anticancer research

Published: January 28, 2026

Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy.

Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 17, 2026

The first case of GOLGA5-RET fusion-positive malignant spindle cell sarcoma of the head and neck responsive to selpercatinib.

The first case of GOLGA5-RET fusion-positive malignant spindle cell sarcoma of the head and neck responsive to selpercatinib.

Journal: International cancer conference journal

Published: May 09, 2025

Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor.

Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 24, 2025

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens.

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 08, 2025

Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients.

Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients.

Journal: Oncology

Published: December 01, 2024

Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.

Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.

Journal: Current problems in cancer

Published: November 08, 2024

Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Journal: Cancers

Published: September 30, 2024

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.

Journal: Thoracic cancer

Published: December 07, 2023

Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.

Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.

Journal: Thoracic cancer

Published: September 30, 2023

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.

Journal: Thoracic cancer

Published: July 25, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026